While PD-1/PD-L1 blockade has become a cornerstone of HNSCC treatment, research is actively exploring ways to enhance immunotherapy efficacy as the overall survival (OS) of these patients still remains poor. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.